ArticleCancer cell2020
IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
168citing papers in PubMed, 2 pooled it
12.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
168 citing papers in PubMed, 2 syntheses or guidelines pooled it, 247 citations in OpenAlex.
- Rheumatoid arthritis reduces the risk of colorectal cancer through immune inflammation mediation.Journal of cellular and molecular medicine · 2024Pooled it
- Revolutionizing breast cancer treatment: Harnessing the related mechanisms and drugs for regulated cell death (Review).International journal of oncology · 2024Pooled it
- An atlas of transcription factor cooperation reveals how motif readers shape regulatory output.bioRxiv : the preprint server for biology · 2026Article
- ERα Micromap (µMap) proximity labeling reveals fulvestrant mechanisms.Nature communications · 2026Article
- Integrative Transcriptional and Chromatin Analyses Reveal Enhancer-Mediated Regulatory Programs Driving Breast Cancer Metastasis.Molecular cancer research : MCR · 2026Article
- Uncovering MYOF as a novel therapeutic target in glioblastoma: mechanistic insights and drug discovery.Cell death discovery · 2026Article
- Multi-omic Profiling of Recurrence Risk Across Breast Cancer Subtypes.medRxiv : the preprint server for health sciences · 2026Article
- Flavonoid-modulated JAK-STAT signaling mitigates malignant transformation and drug resistance in breast tumors: A clinically relevant 3PM-guided innovation.Journal of advanced research · 2026Review
- Regulation of Endoplasmic Reticulum Stress Suppresses Early Pro-Tumorigenic Events During N-Nitrosodiethylamine-Induced Hepatocarcinogenesis.Journal of biochemical and molecular toxicology · 2026Article
- Subtype-specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers.Molecular oncology · 2026Article
- Targeting STAT3-mediated lipid metabolism reprogramming overcomes chemoresistance in acute myeloid leukemia.Cell death & disease · 2026Article
- Review
- Skeletal muscle as an endocrine and paracrine organ in breast cancer biology: a narrative review.Discover oncology · 2026Review
- A Literature Review of Interleukins in the Development and Treatment of Breast Cancer.International journal of molecular sciences · 2026Review
- Allogeneic Immune Cell Perfusion Inhibits the Growth of Vascularized 3D In Vitro Tumor Models, Induces Vascular Regression and Desmoplasia, but Promotes Tumor Cell Invasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Preclinical models of breast cancer metastasis: strengths, limitations, and clinical relevance.NPJ breast cancer · 2026Review
- Mechanistic dissection of GRHL2 and PR transcriptional co-regulation in breast cells.PLoS genetics · 2026Article
- Identification and validation of a novel estrogen-related model for breast cancer to predict the prognosis.Translational cancer research · 2026Article
- Integrative single-cell and machine learning framework reveals prognostic fibroblast subtypes and constructs a fibroblast-related risk signature in lung adenocarcinoma.Scientific reports · 2026Article
- CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer.The Journal of clinical investigation · 2026Article
108 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 7 institutions in 3 countries.
Rasmus SiersbækCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. Electronic address: siersbaek@bmb.sdu.dk.
Valentina ScabiaISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
Sankari NagarajanCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Igor ChernukhinCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Evangelia K PapachristouCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Rebecca BroomeCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Simon J JohnstonNottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK.
Stacey E P JoostenDivision of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Andrew R GreenNottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK.
Sanjeev KumarCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Addenbrookes Hospital, Cambridge CB2 0QQ, UK.
Julia JonesCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Soleilmane OmarjeeCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Ruben Alvarez-FernandezCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Silvia GlontCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Sarah J AitkenCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Kamal KishoreCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Danya CheesemanCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Emad A RakhaNottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK.
Clive D'SantosCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Wilbert ZwartDivision of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, the Netherlands; Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.
Alasdair RussellCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Cathrin BriskenISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
Jason S CarrollCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. Electronic address: jason.carroll@cruk.cam.ac.uk.
Cancer Research UK · GBUniversity of Cambridge · GBUniversity of Nottingham · GBAddenbrooke's Hospital · GBÉcole Polytechnique Fédérale de Lausanne · CHEindhoven University of Technology · NLOncode Institute · NL
Funding
Cancer Research UK 20411Cancer Research UK A20411Wellcome TrustWellcome Trust 108467/Z/15/Z
Abstract
The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a key oncogenic pathway, which has been thought to be functionally connected to estrogen receptor α (ER) in breast cancer. We demonstrate that IL6/STAT3 signaling drives metastasis in ER
Indexed as
AnimalsAntineoplastic Agents, HormonalBreast NeoplasmsEnhancer Elements, GeneticEstrogen Receptor alphaFemaleFulvestrantGene Expression ProfilingGene Expression Regulation, NeoplasticHumansInterleukin-6Kaplan-Meier EstimateMCF-7 CellsMice, Inbred NODMice, KnockoutMice, SCIDAntineoplastic Agents, HormonalEstrogen Receptor alphaFulvestrantInterleukin-6STAT3 Transcription Factorbreast cancerestrogen receptorFOXA1IL6metastasismouse intraductal xenograft modelpioneer factorSTAT3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.